Jesus Berdeja, MD, shares findings from a phase 1 study of talquetamab therapy for relapsed/refractory MM. These data are being presented at the 2021 ASCO Annual Meeting.
Want to check another podcast?
Enter the RSS feed of a podcast, and see all of their public statistics.
